Tabula Rasa Q4 and 2021 guidance

 Future Outlook

Based on current market conditions and our expectations as of today, we are introducing fourth quarter 2021 guidance and revised full year 2021 guidance, as summarized below.

For the fourth quarter 2021, we expect:

• Total revenue in the range of $84 million to $86 million represents growth of 9% to 12%, all of which is organic.
• Adjusted EBITDA in the range of $4 million to $5 million as compared with $4.7 million a year ago.

For the full year 2021, we expect:

• Total revenue in the range of $329.6 million to $331.6 million represents growth of 11% to 12% with organic growth of 7%.
• Adjusted EBITDA in the range of $19.3 million to $20.3 million as compared with $21.8 million a year ago

https://www.biospace.com/article/releases/tabula-rasa-healthcare-reports-third-quarter-2021-results/